Can non‑steroidal anti‑inflammatory drugs be used to treat heavy menstrual bleeding in a reproductive‑age woman without contraindications such as peptic ulcer disease, renal impairment, hypertension, NSAID‑induced asthma, or anticoagulant therapy?

NSAIDs Are Effective for Heavy Menstrual Bleeding in Appropriate Candidates

NSAIDs should be used as a first-line medical therapy for heavy menstrual bleeding in reproductive-age women without contraindications, though they are less effective than tranexamic acid or hormonal options. 1

Efficacy Evidence

NSAIDs reduce menstrual blood loss more effectively than placebo, with evidence showing a mean reduction of approximately 124 mL per cycle 2. However, they rank lower in the treatment hierarchy compared to other medical options:

• Most effective: Levonorgestrel-releasing IUS
• Second tier: Combined hormonal contraceptives, tranexamic acid
• Third tier: NSAIDs (more effective than placebo but less than above options) 3

NSAIDs may be less effective than antifibrinolytics, with patients on NSAIDs being 30% less likely to achieve adequate bleeding reduction compared to tranexamic acid 2. When comparing individual NSAIDs, mefenamic acid and naproxen appear similarly effective 1.

Mechanism and Clinical Use

NSAIDs work by reducing elevated prostaglandin levels in women with heavy menstrual bleeding and provide the added benefit of treating dysmenorrhea 1. This dual action makes them particularly valuable for women experiencing both heavy bleeding and painful periods.

Absolute Contraindications You've Identified

Based on the precautions guideline 4, NSAIDs must be avoided in patients with:

• Active peptic ulcer disease or history of NSAID-associated upper GI bleeding (risk of bleeding recurrence is 5% in first 6 months)
• Significant renal impairment (2% of NSAID users discontinue due to renal complications)
• Uncontrolled hypertension (NSAIDs increase mean blood pressure by 5 mm Hg)
• NSAID-induced asthma, especially with nasal polyps or recurrent sinusitis (prevalence up to 21% in adults with asthma)
• Current anticoagulant therapy (GI bleeding risk increases 3-6 fold; INR increases up to 15%)

Practical Prescribing Algorithm

For women meeting criteria (no contraindications listed above):

1. First choice: Mefenamic acid 500 mg three times daily during menstruation, or naproxen 250-500 mg twice daily
2. Monitor: Blood pressure before starting and periodically during use 5
3. Consider GI prophylaxis if moderate ulcer risk factors present (age >60, concurrent corticosteroids, high-dose NSAIDs): add PPI 4
4. Reassess efficacy after 2-3 cycles; if inadequate response, escalate to tranexamic acid or hormonal therapy 1

Critical Caveats

Pregnancy timing matters: Avoid NSAIDs 6-8 weeks before term due to potential effects on labor and fetal antiplatelet activity 4.

Cardiovascular considerations: While NSAIDs can worsen hypertension and heart failure, naproxen or celecoxib are preferred if NSAID use is necessary in patients with cardiovascular risk factors 5.

Combination therapy: NSAIDs can be used alongside hormonal methods and tranexamic acid to enhance bleeding reduction 6, though this increases complexity and potential side effects.

When NSAIDs Are Insufficient

The evidence clearly shows NSAIDs are less effective than tranexamic acid (which reduces bleeding by 53 mL per cycle) 2 and substantially less effective than the LNG-IUS. If NSAIDs fail to adequately control bleeding after 2-3 cycles, escalate to more effective options rather than continuing ineffective therapy 3.

For women without your listed contraindications, NSAIDs represent a reasonable, accessible first-line option, particularly when dysmenorrhea coexists, but clinicians should maintain low threshold for advancing to more effective therapies if bleeding control is inadequate.